Publications by authors named "Kim A Papp"

Claim this Profile
C
Considerations for Treating Generalized Pustular Psoriasis (GPP): A Narrative Review.
Charles W Lynde, Vimal H Prajapati, Melinda J Gooderham, H Chih-Ho Hong, Mark G Kirchhof, Kim A Papp

Dermatol Ther (Heidelb)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo.
David Rosmarin, Amit G Pandya, Thierry Passeron, Seth B Forman, Jacek Zdybski, Kim A Papp

Dermatol Ther (Heidelb)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III Trials.
Kim A Papp, James Q Del Rosso, Mark G Lebwohl, Melinda J Gooderham, Adelaide A Hebert

Dermatol Ther (Heidelb)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHT.
April Armstrong, Kim A Papp, Mark Lebwohl, Laura J Savage, Keiichi Yamanaka

Dermatol Ther (Heidelb)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasis.
Joseph F Merola, Lyn Guenther, Charles Lynde, Kim A Papp, Lawrence Charles Parish

J Eur Acad Dermatol Venereol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidance.
Kim A Papp, Luis Puig, Jennifer Beecker, Vinod Chandran, Joël Claveau

J Eur Acad Dermatol Venereol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks.
Alan D Irvine, Vimal H Prajapati, Emma Guttman-Yassky, Eric L Simpson, Kim A Papp

Am J Clin Dermatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE study.
Kim A Papp, Shahram Jacobs, Howard Sofen, Michael Bukhalo, Elisa Muscianisi

J Am Acad Dermatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study.
Matthias Augustin, Marie Tauber, Robert Sidbury, Jonathan I Silverberg, Kim A Papp

J Eur Acad Dermatol Venereol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to Onset of Action for Biologics and Targeted Treatments in Psoriasis: Systematic Targeted Literature Review and Network Meta-Analysis.
Kim A Papp, Ron Vender, Kerri Purdy, Fiona Lovegrove, Irina Oroz

Dermatol Ther (Heidelb)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results.
Kim A Papp, Mark G Lebwohl, Lluís Puig, Mamitaro Ohtsuki, Stefan Beissert

Am J Clin Dermatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.
Linda Stein Gold, April W Armstrong, Robert Bissonnette, Nina Magnolo, Ronald B Vender, Kim A Papp

Lancet· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Randomized Trial of BI 730357, an Oral RORγt Inhibitor, for Moderate-to-Severe Plaque Psoriasis.
Melinda J Gooderham, Ulrich Mrowietz, Werner Kadus, Kristin Drda, Hui Gu, Kim A Papp

J Invest Dermatol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Molecular Analysis of IL-17A and IL-23 Pathway Inhibition in Moderate-to-Severe Psoriasis: 4-Week Results from IXORA-R.
Sandra Garcet, Lam C Tsoi, Hong Hur, Andrew Blauvelt, Kim A Papp

J Invest Dermatol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical study.
Stephan Weidinger, Andrew Blauvelt, Kim A Papp, Adam Reich, Chih-Hung Lee

Immunotherapy· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials.
April W Armstrong, Mark Lebwohl, Richard B Warren, Howard Sofen, Akimichi Morita, Kim A Papp

J Eur Acad Dermatol Venereol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial.
Melinda J Gooderham, Javier Alonso-Llamazares, Jerry Bagel, Neal Bhatia, Michael Bukhalo, Kim A Papp

JAMA Dermatol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixekizumab and Malignant Neoplasms: A Pooled Analysis of Data From 25 Randomized Clinical Trials.
Joseph F Merola, Kim A Papp, Atul Deodhar, Andrew Blauvelt, Andris Kronbergs

JAMA Dermatol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase 2 study.
Andrew Blauvelt, Petr Arenberger, Maxwell B Sauder, Megan Couvillion, Roman G Rubio, Kim A Papp

J Am Acad Dermatol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ME3183, an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis.
Kim A Papp, April W Armstrong, Tomokazu Koresawa, Kazunari Otake, Masayuki Hirata

J Eur Acad Dermatol Venereol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canadian Consensus Guidelines for the Management of Vitiligo.
Vimal H Prajapati, Harvey Lui, Yvette Miller-Monthrope, Julien Ringuet, Irina Turchin, Kim A Papp

Dermatol Ther (Heidelb)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canadian Consensus Guidelines for the Management of Atopic Dermatitis with Topical Therapies.
Melinda J Gooderham, H Chih-Ho Hong, Charles Lynde, Kim A Papp, Jensen Yeung

Dermatol Ther (Heidelb)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months.
Diamant Thaçi, Mamitaro Ohtsuki, Julia-Tatjana Maul, Andrea Szegedi, Paula C Luna, Kim A Papp

Dermatol Ther (Heidelb)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.
April W Armstrong, Matthias Augustin, Jennifer L Beaumont, Tan P Pham, Stacie Hudgens, Kim A Papp

Dermatol Ther (Heidelb)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months.
Diamant Thaçi, Mamitaro Ohtsuki, Julia-Tatjana Maul, Andrea Szegedi, Paula C Luna, Kim A Papp

Dermatol Ther (Heidelb)· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis